Peptides News and Research

RSS

Basque researchers find new Alzheimer's-related mechanism

Researchers from the University of the Basque Country have found a new Alzheimer's-related mechanism that could give rise to the development of new therapies against this disease. The study was recently published in the Cell Calcium journal, and the authors have already applied for a European patent to protect the commercial exploitation of this new discovery.

20 May 2010

MicroStockProfit.com releases investment report on Discovery Laboratories

MicroStockProfit.com announces an investment report featuring Discovery Laboratories Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

20 May 2010

Quest PharmaTech net consolidated loss for 2010 increases to $517,799

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced financial and operational results for the fiscal year ended January 31, 2010.

20 May 2010

2010 funding program for Inova Life Sciences - George Mason University research collaboration open

What do you get when you mix a world-class health system with an innovative, entrepreneurial university? A very successful research collaboration.

20 May 2010

Discovery Labs revalidates optimized BAT in program to gain FDA approval of Surfaxin for RDS

Discovery Laboratories, Inc. announces today that the revalidation of its optimized fetal rabbit Biological Activity Test (BAT, an important quality control release and stability test) has been completed, having met all pre-specified acceptance criteria.

19 May 2010

Research findings help explain diverse genetic susceptibility for alcohol use disorders

A genetic variant of a receptor in the brain's reward circuitry plays an important role in determining whether the neurotransmitter dopamine is released in the brain following alcohol intake, according to a study led by researchers at the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health. Dopamine is involved in transmitting the euphoria and other positive subjective effects produced by alcohol.

19 May 2010

Generex Biotechnology's Phase I study data of AE37 for prostate cancer published

Generex Biotechnology Corporation announced today publication of results from the first Phase I study of its lead immunotherapeutic agent AE37 in patients with prostate cancer. At the end of 2009, the Company announced positive interim results from a Phase II trial being conducted with AE37 in patients with breast cancer. The compound is being developed by its wholly-owned subsidiary, Antigen Express, Inc.

19 May 2010

RegeneRx Biopharmaceuticals prices underwritten public offering at $0.41 per unit

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration in cardiovascular diseases, central nervous system injuries, ophthalmic indications and dermal wounds, announced the pricing of its previously announced underwritten public offering of 11,500,000 units of its securities at a public offering price of $0.41 per unit.

19 May 2010

Vect-Horus accentuates its leadership in delivering drugs to the central nervous system

Vect-Horus is a biotechnology company based on the scientific work of Dr. Michel Khrestchatisky and specializes in the development of peptide and pseudo-peptide-based vector molecules for drug targeting and delivery to the central nervous system (CNS).

18 May 2010

IMUC, Torrey Pines Institute identify peptides that generate CD-133 specific T-cells

ImmunoCellular Therapeutics, a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that the Company and Torrey Pines Institute for Molecular Studies in San Diego, CA have identified several peptides which can generate CD-133 specific T-cells. CD-133 is found in high abundance on cancer stem cells ("CSCs") which makes it promising for immunological targeting.

18 May 2010

Emisphere Technologies first-quarter net loss increases to $18.5 million

Emisphere Technologies, Inc. today announced its financial results for the first quarter 2010.

17 May 2010

Soligenix first-quarter revenues decrease to $336,000

Soligenix, Inc., a late-stage biopharmaceutical company, announced today its financial results for the first quarter of 2010.

17 May 2010

Foundation Venture Capital Group makes initial investment of $175,000 to develop test to diagnose AD

As many as 5.3 million Americans, and 35 million people worldwide, are living with Alzheimer's disease, a devastating neurodegenerative illness characterized by memory loss, cognitive decline and widespread destruction of neurons in the brain. Today, there is no definitive diagnosis for the disease, and no treatment to cure it.

15 May 2010

RegeneRx Biopharmaceuticals awarded $3M federal grant to develop heart attack drug

RegeneRx Biopharmaceuticals, Inc. announced today that it has been awarded a $3 million grant from the National Institutes of Health's National Heart, Lung and Blood Institute to support and accelerate the clinical development of its novel product candidate RGN-352, an injectable formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4, for patients who have suffered an acute myocardial infarction, or AMI, commonly known as a heart attack.

14 May 2010

Palatin Technologies reports net loss of $2.0M for third-quarter 2010

Palatin Technologies, Inc., a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics, today announced results for its third quarter ended March 31, 2010.

13 May 2010

New approach to harness and modulate enzyme activity

An Arizona State University graduate student, Jinglin Fu, in collaboration with Biodesign Institute researchers Neal Woodbury and Stephen Albert Johnston, has pioneered a technique that improves on scientists' ability to harness and modulate enzyme activity.

12 May 2010

Biotage extends peptide synthesis research collaboration with University of Copenhagen

Biotage, a leading supplier of tools and technology for medicinal and analytical chemistry, announced an agreement to extend the research collaboration with Professor Knud J. Jensen at the Faculty of Life Sciences, University of Copenhagen, to develop new applications on the Biotage Syro Wave in the field of synthetic peptide and protein chemistry. The collaboration builds on Professor Jensen's previous research in developing novel chemistries for and applications of solid-phase peptide synthesis.

12 May 2010

Researchers develop new method for tracing carbon flux

Microbial communities are performing important functions all around us - from the earth in our flowerpots to the human gut. Now researchers have developed a method for studying the metabolic functions of microbial communities in detail.

12 May 2010

Amorfix, Epitomics collaborate to develop high-affinity monoclonal antibodies against cancer targets

Amorfix Life Sciences and Epitomics, Inc. announced today that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Amorfix has identified several disease specific epitopes (DSEs) on misfolded proteins with their proprietary ProMIS(TM) computational platform discovery technology, which will be used by Epitomics to generate highly specific monoclonal antibodies (mAbs).

11 May 2010

Findings may help develop a new class of drugs for diabetes

More than half a century after researchers identified a promising way to treat diabetes based on blocking the breakdown of insulin in the body, a research team led by a scientist at the Mayo Clinic campus in Florida have developed potent molecules that can do just that.

10 May 2010

Peptides News and Research

Basque researchers find new Alzheimer's-related mechanism

MicroStockProfit.com releases investment report on Discovery Laboratories

Quest PharmaTech net consolidated loss for 2010 increases to $517,799

2010 funding program for Inova Life Sciences - George Mason University research collaboration open

Discovery Labs revalidates optimized BAT in program to gain FDA approval of Surfaxin for RDS

Research findings help explain diverse genetic susceptibility for alcohol use disorders

Generex Biotechnology's Phase I study data of AE37 for prostate cancer published

RegeneRx Biopharmaceuticals prices underwritten public offering at $0.41 per unit

Vect-Horus accentuates its leadership in delivering drugs to the central nervous system

IMUC, Torrey Pines Institute identify peptides that generate CD-133 specific T-cells

Emisphere Technologies first-quarter net loss increases to $18.5 million

Soligenix first-quarter revenues decrease to $336,000

Foundation Venture Capital Group makes initial investment of $175,000 to develop test to diagnose AD

RegeneRx Biopharmaceuticals awarded $3M federal grant to develop heart attack drug

Palatin Technologies reports net loss of $2.0M for third-quarter 2010

New approach to harness and modulate enzyme activity

Biotage extends peptide synthesis research collaboration with University of Copenhagen

Researchers develop new method for tracing carbon flux

Amorfix, Epitomics collaborate to develop high-affinity monoclonal antibodies against cancer targets

Findings may help develop a new class of drugs for diabetes

Editorial Focus eBook - Peptides and Oligonucleotides (2nd edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News